Platform

Nivalis has developed a broad portfolio of proprietary, investigational, small molecule inhibitors of the S-nitrosoglutathione reductase (GSNOR) protein which have been shown in preclinical studies to increase CFTR activity as well as decrease airway inflammation.

Nivalis' drug candidate portfolio consists of multiple compounds which are designed for oral, intravenous (IV), or inhaled administration. The Company’s lead clinical candidate, cavosonstat (N91115), is in clinical testing in CF patients.

Leaving Nivalis.com

Nivalis Therapeutics is not responsible for the content on linked websites.

The document you requested is located on the Journal of Applied Physiology website. A subscription is required to view the document.